Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01556711 · ClinicalTrials.gov registry record
Assessment of Head Injury in the Emergency Department Using BrainScope® Ahead® Technology
A clinical trial, sponsored by BrainScope Company.
- Completed
- Registry status
- 816
- Enrollment target
NCT01556711: Completed study, sponsored by BrainScope Company.
NCT01556711 is a clinical trial that has completed, run by BrainScope Company. The registered enrollment target is 816 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01556711 has completed, sponsored by BrainScope Company.
- COMPLETED
- Registry status
- 816 participants
- Enrollment target
Study Summary
The objectives of the study are to document device performance with respect to the primary and secondary endpoints.
Primary Outcome
Using a BrainScope classification algorithm, the Ahead® M-100 will identify subjects showing sensitivities among 3 classes: Green - brain electrical activity that is consistent with patients without head injuries (Ahead® M-100 output = 1), Yellow - brain electrical activity that is consistent with head injured subjects who are abnormal, but do not have a structural brain injury (Ahead® M-100 output = 2 or 3), Red - brain electrical activity consistent with a structural brain injury observable o
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 816 participants |
| Start Date | 2012-08 |
| Est. Completion | 2013-09 |
What the finished NCT01556711 record still lists
NCT01556711 is an observational study that tracks outcomes without assigning an intervention. The registered 816 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 0 interventions.
NCT01556711 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01556711 about?
NCT01556711 is a clinical study titled "Assessment of Head Injury in the Emergency Department Using BrainScope® Ahead® Technology". The objectives of the study are to document device performance with respect to the primary and secondary endpoints.
What is the current status of trial NCT01556711?
This trial is currently completed. The enrollment target is 816 participants. The study started on 2012-08. Estimated completion is 2013-09.
Who is sponsoring clinical trial NCT01556711?
This trial is sponsored by BrainScope Company, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT07218029 · 815 participants · Phase 3
A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (MK-7962-038)
- NCT04846959 · 818 participants
Study to Evaluate Pregnancy Outcomes in Risankizumab Exposed Pregnancies Relative to Those Non-risankizumab Exposed Pregnancies in Women With FDA Approved Indications
- NCT04028687 · 820 participants
MDR - PMCF Study for Taperloc Complete Stems
- NCT04613440 · 820 participants · NA
FaCT Trial (Facilitated Cascade Testing Trial)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia